Drug Trial Radar · NCT01093326
Clinical Study to Investigate the Long-term Safety, Tolerability, and Efficacy of Ponesimod in Patients With Relapsing-remitting Multiple Sclerosis
Last checked: Nov 20, 2026Latest source record: Mar 30, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
353
Actual
Start
May 12, 2010
Primary completion
Sep 6, 2023
Study completion Sep 6, 2023
Sponsor
- Lead sponsor
- ActelionJohnson & Johnson (Janssen) (JNJ)
- Sponsor type
- Industry
- First posted
- Mar 25, 2010
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years, up to 55 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study is an extension to the study AC-058B201 and will investigate the long-term safety, tolerability and efficacy of ponesimod in patients with relapsing-remitting multiple sclerosis.
Conditions
- Multiple Sclerosis
Interventions
Ponesimod 10 mgDrug
Ponesimod 10 mg oral use
Ponesimod 20 mgDrug
Ponesimod 20 mg oral use
Ponesimod 40 mgDrug
Ponesimod 40 mg oral use
Primary outcomes
What the sponsor says the trial is designed to measure.
- Annualized Relapse Rate (ARR) of Confirmed RelapsesTime frame: From ponesimod start date up to the end of Analysis Period (AP) 3. The actual time varied for each participant and could be up to 13.3 years
- Time to First Confirmed RelapseTime frame: From ponesimod start date up to the end of Analysis Period (AP) 3. The actual time varied for each participant and could be up to 13.3 years
- Time to 24 Weeks Confirmed Disability ProgressionTime frame: From ponesimod baseline up to the end of Analysis Period (AP) 3. The actual time varied for each participant and could be up to 13.3 years
Locations
71 sites in 20 countries. Site status is shown where the registry gives one.
Site not named
Phoenix, Arizona
Site not named
Scottsdale, Arizona
Site not named
Palo Alto, California
Site not named
Sacramento, California
Site not named
Venice, Florida
Site not named
Indianapolis, Indiana
Site not named
Kansas City, Kansas
Site not named
Lenexa, Kansas
Site not named
Latham, New York
Site not named
Schenectady, New York
Site not named
Stony Brook, New York
Site not named
Raleigh, North Carolina
Site not named
Cincinnati, Ohio
Site not named
Columbus, Ohio
Site not named
Burlington, Vermont
Site not named
Kirkland, Washington
Site not named
Vienna, Austria
Site not named
Sofia, Bulgaria
Site not named
Ottawa, Ontario, Canada
Site not named
Brno, Czechia
Site not named
Jihlava, Czechia
Site not named
Olomouc, Czechia
Site not named
Ostrava-Poruba, Czechia
Site not named
Prague, Czechia
Site not named
Teplice, Czechia
Site not named
Helsinki, Finland
Site not named
Hyvinkää, Finland
Site not named
Tampere, Finland
Site not named
Turku, Finland
Site not named
Montpellier, France
Site not named
Berlin, Germany
Site not named
Essen, Germany
Site not named
Ulm, Germany
Site not named
Budapest, Hungary
Site not named
Esztergom, Hungary
Site not named
Győr, Hungary
Site not named
Miskolc, Hungary
Site not named
Tel HaShomer, Israel
Site not named
Tsrifin, Israel
Site not named
Breda, Netherlands
Showing 40 of 71 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.